In conclusion, we found that as liver fibrosis progressed, plasma and tissue GAS5 levels increased, whereas the development of cirrhosis was associated with the downregulation of plasma GAS5 in patients with NAFLD. This evidence concerns the gene GAS5 and metabolic dysfunction-associated steatotic liver disease.